Skip to the content
[email protected]
Get in Touch
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
Menu
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
[email protected]
Get in Touch
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
Menu
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
NEWS
Highlights
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
NEWS
NEWS 2023
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
December 15, 2023
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
Read More
November 13, 2023
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
Read More
October 25, 2023
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
Read More
September 27, 2023
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
Read More
September 27, 2023
Appili Therapeutics Presents at the 10th International Tularemia Conference
Read More
September 25, 2023
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
Read More
August 11, 2023
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
Read More
June 29, 2023
Appili Therapeutics Announces Bridge Loan from Bloom Burton & Co.
Read More
June 23, 2023
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
Read More
May 24, 2023
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
Read More
May 8, 2023
Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy
Read More
April 18, 2023
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
Read More
April 3, 2023
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
Read More
March 20, 2023
Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
Read More
February 14, 2023
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
Read More
February 8, 2023
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
Read More
January 17, 2023
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
Read More
January 13, 2023
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
Read More
